301 related articles for article (PubMed ID: 16809300)
1. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.
Abdel-Motal U; Wang S; Lu S; Wigglesworth K; Galili U
J Virol; 2006 Jul; 80(14):6943-51. PubMed ID: 16809300
[TBL] [Abstract][Full Text] [Related]
2. Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes.
Abdel-Motal UM; Wang S; Awad A; Lu S; Wigglesworth K; Galili U
Vaccine; 2010 Feb; 28(7):1758-65. PubMed ID: 20034607
[TBL] [Abstract][Full Text] [Related]
3. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells.
Abdel-Motal UM; Guay HM; Wigglesworth K; Welsh RM; Galili U
J Virol; 2007 Sep; 81(17):9131-41. PubMed ID: 17609270
[TBL] [Abstract][Full Text] [Related]
5. Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.
Galili U
Vaccine; 2020 Sep; 38(42):6487-6499. PubMed ID: 32907757
[TBL] [Abstract][Full Text] [Related]
6. Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.
Galili U
Med Res Arch; 2021 Jul; 9(7):. PubMed ID: 34853815
[TBL] [Abstract][Full Text] [Related]
7. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.
Kumar R; Tuen M; Li H; Tse DB; Hioe CE
Vaccine; 2011 Nov; 29(48):9064-74. PubMed ID: 21945958
[TBL] [Abstract][Full Text] [Related]
8. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells.
Manches O; Plumas J; Lui G; Chaperot L; Molens JP; Sotto JJ; Bensa JC; Galili U
Haematologica; 2005 May; 90(5):625-34. PubMed ID: 15921377
[TBL] [Abstract][Full Text] [Related]
9. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
10. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the alpha1,3galactosyltransferase gene.
Deriy L; Ogawa H; Gao GP; Galili U
Cancer Gene Ther; 2005 Jun; 12(6):528-39. PubMed ID: 15818383
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
12. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
[TBL] [Abstract][Full Text] [Related]
13. [Immunogenicity of recombinant adeno-asscociated virus type 1 expressing HIV-1 gp120 gene in mice and Rhesus macaques].
Yu SQ; Feng X; Liu HM; Yang HR; Li HX; Zeng Y
Bing Du Xue Bao; 2010 Mar; 26(2):115-20. PubMed ID: 20480640
[TBL] [Abstract][Full Text] [Related]
14. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.
Galili U
Immunol Cell Biol; 2005 Dec; 83(6):674-86. PubMed ID: 16266320
[TBL] [Abstract][Full Text] [Related]
15. The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.
Hioe CE; Visciano ML; Kumar R; Liu J; Mack EA; Simon RE; Levy DN; Tuen M
Vaccine; 2009 Dec; 28(2):352-60. PubMed ID: 19879224
[TBL] [Abstract][Full Text] [Related]
16. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.
Banerjee K; Andjelic S; Klasse PJ; Kang Y; Sanders RW; Michael E; Durso RJ; Ketas TJ; Olson WC; Moore JP
Virology; 2009 Jun; 389(1-2):108-21. PubMed ID: 19410272
[TBL] [Abstract][Full Text] [Related]
18. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.
Azizi A; Anderson DE; Ghorbani M; Gee K; Diaz-Mitoma F
BMC Immunol; 2006 Oct; 7():25. PubMed ID: 17076905
[TBL] [Abstract][Full Text] [Related]
20. GP120: target for neutralizing HIV-1 antibodies.
Pantophlet R; Burton DR
Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
